SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors speculate on a major buyout and a potential short squeeze, fueled by record short interest and anticipation for upcoming trial data. The community is heavily focused on the stock's upward momentum and the intense pressure building on short sellers to cover their positions before the weekend.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending due to intense volatility and extreme community polarization regarding Michael Saylor's leveraged Bitcoin-accumulation strategy, with the stock experiencing sharp downward pressure that has left many investors debating whether this represents a generational buying opportunity or a looming insolvency event. Traders are intensely focused on market-maker activity, options expiration, and the company's reliance on share dilution to maintain its Bitcoin holdings as broader market sentiment toward the crypto sector remains highly uncertain.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is trending due to significant momentum in the memory and storage sector, driven by strong AI-related demand and an ongoing rally among industry peers. The community remains divided, with many traders debating whether the stock is undergoing a structural rerating or experiencing an unsustainable parabolic bubble fueled by retail FOMO and institutional rotation.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor Corp. is trending as investors weigh the strategic potential of its major all-stock acquisition of Synaptics against immediate concerns regarding share dilution and execution risk. The community remains divided between those bracing for further downside due to the complex integration, and those viewing the current price pullback as an attractive entry point to capitalize on long-term growth in edge AI and industrial power infrastructure.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is facing intense volatility and selling pressure as investors grapple with debt concerns, leadership criticism, and the company's recent move into AI infrastructure partnerships. The community remains deeply divided, with some traders viewing the current price as a tactical buying opportunity while others express significant skepticism regarding management's strategic direction and the impact of the ongoing steel price environment.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors monitor an upcoming court hearing over commercial rights alongside high anticipation for an August PDUFA decision for Deramiocel. The community is actively debating the impact of these legal proceedings on the company's path to market and the potential for a favorable FDA label expansion given the positive phase 3 and long-term extension data.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors react to robust clinical data from its next-generation obesity pipeline, including strong results for retatrutide and Foundayo. The stock is seeing significant institutional attention and bullish sentiment, with market participants actively discussing its competitive dominance in the GLP-1 sector and strategic expansion into broader indications like oncology and neuroscience.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is currently a focal point of intense community speculation, with retail investors attempting to force a short squeeze by piling into shares and encouraging long-term holding to counteract short-selling pressure. The trend is fueled by nostalgia for fast-food culture and a narrative that the company's dividend-paying fundamentals and potential for a corporate turnaround make it an undervalued, meme-worthy target similar to past retail-driven market events.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense community discussion surrounding its production scaling efforts, specifically the goal to increase capacity to one million units per month within the next year. While many investors are bullish on the potential for massive revenue growth and the company's role in AI infrastructure, others remain skeptical due to past timeline shifts and are closely monitoring the upcoming annual meeting for concrete evidence of execution.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors weigh the potential impact of a long-awaited appellate court decision regarding Medicare bundling against the company's strong revenue growth and expanding commercial presence. The community is actively debating the stock's valuation disconnect and potential consolidation in the nephrology sector, with many long-term shareholders remaining focused on fundamental execution while monitoring institutional activity for signs of a turnaround.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

HBPEHBP Energy Corp

Latest HBPE News